A phase II study of neratinib, pertuzumab, and trastuzumab with paclitaxel followed by doxorubicin and cyclophosphamide in HER2+ primary IBC, and neratinib with paclitaxel followed by doxorubicin and cyclophosphamide in HR+/HER2− primary IBC is ongoing (ClinicalTrials.gov Identifier: NCT03101748; Table 1) [42]. Here, ERBB2 is linked to inflammatory breast carcinoma.